Jpmorgan Chase & Co »

Biomarin Pharmaceutical shares owned by Jpmorgan Chase & Co

Quarter-by-quarter ownership of Biomarin Pharmaceutical shares owned by Jpmorgan Chase & Co from 13F filings

Historical chart of Jpmorgan Chase & Co investment in Biomarin Pharmaceutical

Tip: Access up to 7 years of quarterly data

All positions including Biomarin Pharmaceutical held by Jpmorgan Chase & Co consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Biomarin Pharmaceutical by Jpmorgan Chase & Co

Quarter filed Position value Share count Share price at filing
2023-12-31 $5.6M 5.4M 1.03
2023-09-30 $386k 389k 0.99

More positions owned by Jpmorgan Chase & Co

Microsoft Corp Common (MSFT)
Apple Common (AAPL)
Amazon Common (AMZN)
Spdr S&p 500 Etf Trust Fund (SPY)
Nvidia Corporation Common (NVDA)
Meta Platforms Common (META)
Unitedhealth Group Common (UNH)
Vanguard Total Intl Bond Etf Fund (BNDX)
Alphabet Common (GOOG)
Eli Lilly & Co Common (LLY)
Mastercard Incorporated Common (MA)
Alphabet Common (GOOGL)
Abbvie Common (ABBV)
Vanguard Total Bond Market Fund (BND)
Tesla Common (TSLA)

View all positions for Jpmorgan Chase & Co

Top funds holding Biomarin Pharmaceutical

MacKay Shields
Lazard Asset Management
Wellesley Investment Advisors
iA Global Asset Management
Victory Capital Management
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
Shenkman Capital Management
Bank of America Corporation
Jpmorgan Chase & Co
Wellington Management Company
Amundi
New York State Common Retirement Fund
Bnp Paribas Investment Partners
SSI Investment Management
La Banque Postale Asset Management SA

View all funds holding Biomarin Pharmaceutical